Brain-homing CD4⁺ T cells display glucocorticoid-resistant features in MS

Steven C. Koetzier, Jamie van Langelaar,* Katelijn M. Blok, MD,* Thierry P.P. van den Bosch, PhD, Annet F. Wierenga-Wolf, Marie-Josée Melief, Kim Pol, Theodora A. Siepman, MD, Georges M.G.M. Verjans, PhD, Joost Smolders, MD, PhD, Erik Lubberts, PhD, Helga E. de Vries, PhD, and Marvin M. van Luijn, PhD

Abstract

Objective
To study whether glucocorticoid (GC) resistance delineates disease-relevant T helper (Th) subsets that home to the CNS of patients with early MS.

Methods
The expression of key determinants of GC sensitivity, multidrug resistance protein 1 (MDR1/ABCB1) and glucocorticoid receptor (GR/NR3C1), was investigated in proinflammatory Th subsets and compared between natalizumab-treated patients with MS and healthy individuals. Blood, CSF, and brain compartments from patients with MS were assessed for the recruitment of GC-resistant Th subsets using fluorescence-activated cell sorting (FACS), quantitative polymerase chain reaction (qPCR), immunohistochemistry, and immunofluorescence.

Results
An MS-associated Th subset termed Th17.1 showed a distinct GC-resistant phenotype as reflected by high MDR1 and low GR expression. This expression ratio was further elevated in Th17.1 cells that accumulated in the blood of patients with MS treated with natalizumab, a drug that prevents their entry into the CNS. Proinflammatory markers C-C chemokine receptor 6, IL-23R, IFN-γ, and GM-CSF were increased in MDR1-expressing Th17.1 cells. This subset predominated the CSF of patients with early MS, which was not seen in the paired blood or in the CSF from patients with other inflammatory and noninflammatory neurologic disorders. The potential of MDR1-expressing Th17.1 cells to infiltrate brain tissue was confirmed by their presence in MS white matter lesions.

Conclusion
This study reveals that GC resistance coincides with preferential CNS recruitment of pathogenic Th17.1 cells, which may hamper the long-term efficacy of GCs in early MS.

*Both authors contributed equally to the manuscript.

From the Departments of Immunology (S.C.K., J.v.L., A.F.W.-W., M.-J.M., K.P., J.S., M.M.v.L.); Neurology (K.M.B, T.A.S., J.S.); Pathology (T.P.P.v.d.B.); Viroscience (G.M.G.M.V.); Rheumatology (E.L.); and MS Center ErasMS at Erasmus MC (S.C.K, J.v.L., K.M.B, A.F.W.-W, M.-J.M., K.P., T.A.S., J.S., M.M.v.L.), University Medical Center, Rotterdam, The Netherlands; Research Center for Emerging Infections and Zoonosis (G.M.G.M.V.), University of Veterinary Medicine, Hannover, Germany; Department of Neuroimmunology (J.S.), Netherlands Institute for Neuroscience, Amsterdam; Department of Molecular Cell Biology and Immunology (H.E.d.V.), Amsterdam University Medical Center, MS Center Amsterdam, Amsterdam Neuroscience, the Netherlands.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Early MS is characterized by waves of brain-infiltrating immune cells that drive inflammation within the CNS, resulting in demyelination and eventually neurodegeneration. Glucocorticoids (GCs) are broad-spectrum immunosuppressive drugs that are used as standard regimen to dampen acute exacerbations in MS. (GCs) are broad-spectrum immunosuppressive drugs that are used as standard regimen to dampen acute exacerbations in MS. Although GCs effectively relieve clinical symptoms, these drugs do not halt subsequent exacerbations or disease progression. Of interest, blood cells of patients with relapsing-remitting MS (RRMS) show reduced sensitivity to GCs, indicating a limited window of opportunity for inducing long-term efficacy of this MS treatment. To achieve this, more insights into the underlying mechanisms of GC insensitivity are required in early MS.

On binding its ligand, the glucocorticoid receptor (GR/NR3C1) hyperphosphorylates, forms dimers with other nuclear receptors, and translocates into the nucleus. Within the nucleus, these dimers recognize GR elements in promoter regions or interact with transcription factors to transactivate or repress proinflammatory gene expression. Apart from binding to the GR, GCs can be excreted out of the cell by the multidrug resistance protein 1 (MDR1/ABCB1).

In experimental autoimmune encephalitis (EAE) mice, the therapeutic efficacy of GCs depends on the suppression of CNS recruitment of proinflammatory CD4+ T helper (Th) cells. Because GCs are unable to induce long-term protective effects in MS, it is tempting to speculate that certain pathogenic Th cells avoid GC-mediated suppression and thereby contribute to recurrent disease activity. C-C chemokine receptor 6 (CCR6) expression on memory Th cells promotes their recruitment into the CNS and is essential for the induction of EAE. In patients with RRMS, blood-derived CCR6+ and not CCR6− memory Th cells show increased proinflammatory capacity in response to myelin peptides. Previously, our group revealed that a human pathogenic CCR6+ Th subset commonly termed TH17.1 (interleukin IL-17low interferon IFN-γhigh granulocyte-macrophage colony-stimulating factor GM-CSFhigh) is associated with early MS. Of interest, we and others found that TH17.1 cells from patients with RRMS treated with natalizumab for 12 months and frozen down until further use. The use of primary material and experimental procedures were approved by the medical ethics committee of each respective center.

**Antibodies and flow cytometry**

The anti-human monoclonal antibodies used for flow cytometry are described in supplementary table 1A (links.lww.com/NXI/A32S). For MDR1 surface staining, cells were taken up in Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific) containing 2% fetal calf serum and 25 μM cyclosporin A (Sigma-Aldrich, St Louis, MO), which allows for a conformational change exposing the epitope or absolute ethanol (Merck, Schiphol-Rijk, The Netherlands) as a vehicle control. Subsequently, MDR1 (Biolegend, London, UK) antibody was added, and cells were incubated for 20 minutes at 37°C and 5% CO₂. Cells were stained using Fixable Viability (L/D) Stain 700 (BD Biosciences, Erembodegem, Belgium), eFluor 506, or eFluor 520 (Thermo Fisher Scientific, Landsmeer, The Netherlands) in the dark for 15 minutes at 4°C. Other surface markers were stained in the dark for 30 minutes at 4°C. C55-Annexin V (BD Biosciences) was added in the presence of calcium chloride to deplete early apoptotic (Annexin V−Live/Dead+) memory CD4+ Th cells. Cells were measured using the LSRII-Fortessa or FACSaria-III flow cytometer and analyzed using FACSDiva software (Version 8.0.1; BD Biosciences).

**Cell sorting**

CD4+ cells were isolated from fresh healthy blood donors (Sanquin, Amsterdam, The Netherlands) using CD4 microbeads and the autoMACS Pro Separator (both Miltenyi Biotec, Bergisch Gladbach, Germany) and were frozen down until further use. After thawing, CCR6+ memory Th populations (CD3+CD4+CD8−CD25−CD45RA−CD45RO+) were isolated using a FACSaria-III machine. CCR6+ memory Th
subsets were further defined based on differential expression of CXCR3 and CCR4; Th17 (CCR6⁺CXCR3⁻CCR4⁺), Th17 double-positive ("DP"; CCR6⁺CXCR3⁺CCR4⁺) and Th17.1 (CCR6⁻CXCR3⁻CCR4⁻/dim).14 Freeze-thawing effects on CCR6 and CXCR3 expression are displayed in supplementary figure 1A (links.lww.com/NXI/A323).

RNA isolation and quantitative PCR
RNA isolation, complementary DNA synthesis, and real-time quantitative PCRs were performed as previously described.13 Primer-probe sets were designed using the Universal ProbeLibrary (Roche Applied Science, Penzberg, Germany). Apart from IFNG and CSF2, which were measured after Phorbol 12-myristate 13-acetate and ionomycin stimulation, gene expression was measured in unstimulated cells.13 An overview of all used primer sequences can be found in supplementary table 1B (links.lww.com/NXI/A325). RNA samples containing less than 75 ng total RNA were excluded from the analysis.

In vitro proliferation and apoptosis assay
CD4⁺ cells from healthy blood donors were thawed and labeled with 0.075 μM CellTrace carboxyfluorescein succinimidyl ester according to the manufacturer’s instructions (Thermo Fisher Scientific). After washing, Th17 and Th17.1 memory cells were purified using FACS, as described above. Sorted Th17 and Th17.1 cells were plated at 2.5 × 10⁵ cells/mL and activated with aCD3/CD28 dynabeads (1:5; Thermo Fisher Scientific) for 3 days. Cells were cultured in RPMI 1640 supplemented with 1% penicillin/streptomycin (Lonza, Verviers, Belgium), 5% human AB serum (Sanquin), and 75 μM methylprednisolone sodium succinate (Pfizer, Capelle a/d IJssel, The Netherlands) or a vehicle control. A similar concentration of methylprednisolone sodium succinate was used in all experiments. After 3 days of culture, cells were exposed to methylprednisolone in a similar manner as described above. As a positive control for apoptosis induction, 1 × 10⁶ healthy donor peripheral blood mononuclear cells were exposed to a temperature of 65°C for 20 minutes, put on ice, and mixed with the same amount of nonexposed cells.

Rhodamine efflux and MDR1 shift assay
We combined a rhodamine 123 (Rh123) efflux and MDR1 shift assay to measure both the efflux potential and MDR1 expression of each Th17 subset.15,19 Peripheral blood mononuclear cells were thawed and resuspended in RPMI 1640 containing 2% fetal calf serum. Cells were resuspended at a concentration of 1 × 10⁶ cells/mL and were incubated with Rh123 (0.5 μg/mL) or a vehicle control (ethanol; both Sigma-Aldrich) in the dark and on ice for 30 minutes. Cells were
washed and supplemented with and without cyclosporin A (25 μM). Next, MDR1 antibody (supplementary table 1A, links.lww.com/NXI/A325) was added to all tubes for 2 hours at 37°C and 5% CO₂, after which cells were stained with Th17 subset-defining antibodies as described above. In this way, we could analyze the efflux potential in one tube (Rh123 without cyclosporin A) and both the blocking of this efflux and MDR1 surface expression in another tube (Rh123 with cyclosporin A) for each subset.

In vitro transmigration assay
Memory Th cells (CD3⁺CD8⁻CD25lowCD45RA⁻) were separated from fresh, MACS-sorted CD4⁺ cells using FACS. Trans-endothelial migration was assessed using 5 × 10⁵ memory Th cells and transwell plates coated with a confluent monolayers of human brain endothelial cells (hCMEC/D3 cell line) as previously described.¹³,²¹,²² Migration was performed for 4 hours at 37°C and 5% CO₂. All experiments were performed in duplicate. The average percentages of CCR6⁺ Th subsets were compared before and after migration.

Immunohistochemistry and multiplex immunofluorescence
Immunohistochemistry was performed with an automated, validated, and accredited staining system Ventana Benchmark ULTRA using the OptiView Universal DAB Detection Kit (both Ventana Medical Systems, Oro Valley, AZ). In brief, after deparaffinization and heat-induced antigen retrieval, 7-μm-thick brain sections were incubated with the antibody of interest for 32 minutes. This was followed by a hematoxylin II counter staining for 12 minutes and the addition of a blue coloring reagent for 8 minutes according to the manufacturer’s instructions (both Ventana Medical Systems). To assess MDR1 expression on Th cells, immunofluorescent staining for MDR1 and CD4 was performed using the automated multiplex platform Benchmark Discovery (Ventana Medical Systems). In short, brain sections were deparaffinized and antigen retrieved with cell conditioning 1 (Ventana Medical Systems) for 32 minutes. Tissue slides were incubated with MDR1 antibody for 32 minutes at 37°C, followed by detection with fluorescein amidite (Roche Applied Science). Antibody denaturation was performed using CC2 (Ventana Medical Systems) for 8 minutes at 100°C. Subsequently, CD4 antibody was incubated for 32 minutes at 37°C, followed by detection with Cy5 (Roche Applied Science). Finally, slides were washed in phosphate-buffered saline and mounted with Vectashield containing 4',6'-diamidino-2-phenylindole (Vector laboratories, Peterborough, UK). For detailed information of the used antibodies, see supplementary table 1A (links.lww.com/NXI/A325).

Statistical analysis
Statistical tests were performed using GraphPad Prism 5 software and are described in each figure legend. Results are displayed as individual data points with/without the standard error of the mean or as a box and whiskers plot. For all tests, a p value of <0.05 (*) was considered significant.

Data availability
On request from qualified investigators, any acquired data not published within this article are available. If desired, please contact the corresponding author of this article.

Results
High ABCB1 and low NR3C1 expression defines GC-resistant Th17.1 cells with enhanced proinflammatory capacity
GC sensitivity is determined by the expression of ABCB1 (MDR1) and NR3C1 (GR) (figure 1A). Using an MDR1 shift assay, we found that MDR1 was predominantly expressed on CCR6⁺ vs CCR6⁻ memory Th cells within the blood of healthy individuals (p < 0.001; figure 1, B and C), indicating that high MDR1 expression is not associated with Th1 cells. After subdivision of CCR6⁺ Th cells into functionally distinct subsets based on CXCR3 and CCR4 expression, MDR1 was abundant on Th17.1 (CCR6⁺CXCR3⁺CCR4⁻dim, IL-17lowIFN-γhighGM-CSFhigh) compared with Th17 (CCR6⁺CXCR3⁻CCR4⁺, IL-17highIFN-γnegGM-CSFdim) and Th17 DP (CCR6⁺CXCR3⁺CCR4⁺, IL-17highIFN-γlowGM-CSFdim) cells from the same blood donors (p < 0.001 and p < 0.01; figure 1, D and E). Subsequently, we sorted these populations and analyzed coexpression of MDR1 (ABCB1) with GR (NR3C1). NR3C1 was selectively downregulated in Th17.1 cells (p < 0.05; figure 1F), resulting in strongly elevated ABCB1/NR3C1 expression ratios (p < 0.001; figure 1G). In vitro experiments confirmed that proliferating Th17.1 cells and MDR1⁻ fractions in particular were less sensitive to methylprednisolone compared with paired Th17 cells (figure 1H). This is probably not related to apoptotic effects because methylprednisolone hardly induced early and late apoptosis of memory Th cells under similar conditions (supplementary figure 2A, links.lww.com/NXI/A323).²³,²⁴ Th17.1-associated genes IL-23 receptor (IL23R), IFN-γ (IFNG), and GM-CSF (CSF2) displayed elevated expression in MDR1⁻ vs MDR1⁺ fractions of Th17.1 (p < 0.01 vs p < 0.05, respectively; figure 1I). In contrast to DNA accessory molecule 1, expression levels of adhesion molecules P-selectin glycoprotein ligand 1 and very late antigen 4 were increased on MDR1⁺ compared with paired Th17 cells (see supplementary figure 1B, links.lww.com/NXI/A323). These findings show that Th17.1 cells have a distinctive GC-resistant phenotype, which probably contributes to their role in MS disease activity.¹³

Th17.1 cells trapped in the blood of natalizumab-treated patients with MS show increased ABCB1 and reduced NR3C1 expression
In our previous study, Th17.1 cells were found to selectively accumulate in the blood from patients with MS who clinically responded to natalizumab treatment.¹⁷ This peripheral entrapment makes it possible to analyze the GC resistance profile of Th17.1 cells that infiltrate the CNS during early MS. After sorting of these and other CCR6⁺ memory Th cells from the blood, we found selectively increased ABCB1 expression in Th17.1 cells from 11 patients with RRMS who clinically responded to natalizumab treatment vs 9 age- and sex-matched
healthy controls ($p < 0.05$; figure 2A). This was not found in patients who experienced clinical relapses despite natalizumab therapy (nonresponders; $n = 6$; figure 2A). Despite the fact that all nonresponders were female, sex did not affect expression profiles within the whole group of patients and controls (data not shown). NR3C1 was reduced in all CCR6$^+$ Th subsets analyzed from these patients, which was only significant in nonresponders and mainly found in Th17.1 (figure 2A). As a result, ABCB1/NR3C1 expression ratios were enhanced especially in natalizumab responders compared with healthy controls (figure 2A). Although the frequencies of MDR1$^+$ Th17.1 cells were elevated in the responders ($p < 0.05$), we did not find...
differences in MDR1 surface expression (supplementary figure 1C, links.lww.com/NNX/A323) or Rh123 dye efflux (figure 2, B and C) for Th17.1 cells between these groups. CSF-homing marker CCR6 was higher expressed on MDR1+ vs MDR1− Th17.1 cells from the blood of natalizumab-treated patients with MS (p < 0.0001), which was not seen for CXCR3 (figure 2D). These data show that GC-resistant Th17.1 cells have a phenotype associated with preferential recruitment to the CSF in early MS.

**MDR1+ Th17.1 cells are enriched in the CSF of patients with early MS and not in patients with other neurologic disorders**

Ex vivo flow cytometric analysis of paired blood and CSF samples from treatment-naïve patients with early MS (n = 9, table 1) revealed a significant rise in MDR1-expressing CD4+ (p < 0.0001) and not CD8+ T memory cells, resulting in increased CD4/CD8 ratios (p < 0.001) within the CSF (figure 3A). CCR6-expressing memory Th cells were increased in paired CSF vs blood samples from patients with early MS (p < 0.0001; supplementary figure 1D, links.lww.com/NNX/A323) and expressed higher surface levels of MDR1 than CCR6 memory fractions in MS CSF (p < 0.0001; figure 3B). Th17.1 predominated the CSF of patients with early MS compared with Th17 and Th17 DP cells (n = 15, table 1 and p < 0.001, figure 3C). This selective enrichment was not found in paired blood samples or in the CSF of 8 patients with other inflammatory or noninflammatory neurologic disorders (table 1 and figure 3C). The predominance of Th17.1 cells in early MS CSF was even more apparent when analyzing MDR1-expressing proportions (p < 0.001; figure 3D). Within the blood of these patients, CCR6 and not CXCR3 was enriched on MDR1+ compared with MDR1− Th17.1 cells (p < 0.0001 and p < 0.01; figure 3E). MDR1+ Th17.1 cells in the CSF showed higher CXCR3 levels than their counterparts in the blood (p < 0.05; figure 3E). The enhanced recruitment of MDR1+ Th17.1 cells to early MS CSF shows that this subset preferentially migrates across blood-CNS barriers, which was confirmed in vitro (supplementary figure 2B and C, links.lww.com/NNX/A323).

**MDR1-expressing CD4+ T cells are recruited to MS brain tissue and show a Th17.1 phenotype**

To study whether MDR1high Th17.1 cells also infiltrate the inflamed MS brain, we first performed in situ analyses of postmortem white matter tissues from 3 late-stage MS donors showing a high number of perivascular infiltrates. Immunohistochemical analysis for MDR1 and CD4 revealed their coexistence in perivascular areas of active lesions (figure 4, A and B). Besides the expected presence of MDR1 in other CNS-resident cells,25 we were able to validate the coexpression of MDR1 with CD4 using confocal microscopy (figure 4C). To address how MDR1 was expressed among MS brain-infiltrating CCR6+ Th subsets, we analyzed ex vivo single-cell suspensions of postmortem blood, meninges, and white matter tissues from 8 late-stage MS donors using flow cytometry (figure 4, D and E). Although a trend increase was seen for the amount of CCR6+ memory Th cells in the brain and meninges compared with blood, this was not significant (Supplementary figure 1E, links.lww.com/NNX/A323). CXCR3+ memory Th cells were enriched in brain vs meningeal and blood samples and showed highest MDR1 expression in brain tissues (p < 0.05; Supplementary figure 1F, links.lww.com/NNX/A323). CD8+ memory T cells showed a similar trend, yet not significant (Supplementary figure 1G, links.lww.com/NNX/A323). In contrast to Th17 and Th17 DP cells, frequencies of MDR1+ Th17.1 cells were significantly increased in brain tissue compared with meninges (p < 0.05) and blood (p < 0.0001; both figure 4E). Although not significant, Th17.1 also seemed to be more present in the meninges than in the blood and were more abundant than Th17 DP cells in brain tissues. Overall, these findings support the use of MDR1 as a marker to delineate CNS-homing, potentially pathogenic Th cells in patients with early MS.

**Discussion**

CSF from patients with early MS is characterized by increased numbers of CD4+ and not CD8+ T cells.18,26 Because GCs are used to dampen acute MS relapses, we examined GC resistance features among different pathogenic CD4+ Th cell subsets during early MS. Our results demonstrate that Th17.1 cells display a unique GC-resistant (ABCB1highNR3C1low) phenotype, which is accompanied by a selective enrichment in the CSF from patients with early MS and not in patients with other neurologic diseases. The fact that this potentially GC-resistant Th subset is also localized in MS white matter lesions puts Th17.1 cells and particularly MDR1 forward as a promising target for predicting and boosting GC treatment efficacy in early MS.

Several factors may be responsible for the selective upregulation of ABCB1 (MDR1) and downregulation of NR3C1 (GR) in Th17.1 cells. A pathogenic feature of MS is chronic activation of the hypothalamus-pituitary-adrenal (HPA) axis, resulting in elevated levels of the natural GC cortisol.5 Because GCs can also upregulate MDR127 and downregulate GR,28–30 such increased levels may trigger GC-resistant, brain-homing Th17.1 cells in MS. Chronic inflammation was also found to upregulate MDR1 expression on lymphocytes via activation of signal transducer and activator of transcription 3 (STAT3) protein.31 Consistently, STAT3 drives the expression of RAR-related orphan nuclear receptor γt (RORγt), which inhibits GC action32 and is highly abundant in Th17.1 cells.13 This probably also explains our finding that the MDR1+ subset of Th17.1 expresses high levels of GM-CSF, which is directly controlled by RORγt.33 Of note, steroid receptor coactivators, which control GR responses,34 have been recently linked to RORγt-dependent pathogenic Th17 differentiation.35 In addition, IL-2 is not only an important trigger of GM-CSF in Th memory cells from patients with MS36 but is also able to reduce GR expression.37 In EAE,
Figure 2 Increased frequencies of MDR1+ Th17.1 cells in the blood of natalizumab-treated patients with MS compared with healthy controls

(A) ABCB1, NR3C1, and ABCB1/NR3C1 expression ratios for Th17, Th17 DP, and Th17.1 cells from thawed peripheral blood mononuclear cells of patients with MS who clinically responded (n = 10–11) or did not respond (n = 5–7) to natalizumab treatment and age- and sex-matched healthy controls (n = 6–9). Data were analyzed using Kruskal-Wallis tests. (B) Representative FACS plot showing Rh123 efflux in Th17, Th17 DP, and Th17.1 cells. (C) Frequencies of MDR1+ Th17, Th17 DP, and Th17.1 cells within Th cells (top) and percentages of Rh123-negative cells within each subset (bottom) for 11 natalizumab-treated patients with MS and 5 healthy controls. Data were compared using Kruskal-Wallis tests. (D) CCR6 and CXCR3 expression (MFI) on MDR1− vs MDR1+ Th17.1 cells from 11 natalizumab-treated patients with MS. Data were analyzed using paired t-tests. *p < 0.05, **p < 0.01, ****p < 0.0001. HC = healthy control; MDR1 = multidrug resistance protein 1; NR = did not respond; NTZ= natalizumab; R = responded; Rh123 = rhodamine 123; Th = T helper.
macrophage migration inhibitor factor induced GC resistance of Th cells via upregulation of T-box transcription factor (T-bet), another Th17.1-associated transcription factor. In parallel with this, we found that T-bet-dependent IFN-γ was upregulated in MDR1+ Th17.1 cells. Together, these studies indicate that the GC-resistant phenotype of Th17.1 may be induced by combined effects of a hyperactive HPA axis and chronic inflammation in patients with MS.

For MDR1, transcript levels were selectively increased in Th17.1 cells that accumulated in the blood from clinical responders to natalizumab. This also corresponds to the increased very late antigen 4 expression on MDR1+ vs MDR1− Th17.1 cells. MDR1 surface expression was not increased on Th17.1 cells from responders. One limitation of this study is that we did not analyze total protein levels of MDR1, which could explain this discrepancy. Furthermore, posttranslational
regulation of MDR1 such as altered intracellular trafficking and localization may be different, especially after induction by cyclosporin A. For GR, expression levels were downregulated in all CCR6+ Th subsets from the blood of natalizumab responders and were further reduced in nonresponders. A possible explanation for this is that HPA axis hyperactivity is more pronounced in patients with progressive MS such as patients not responding to natalizumab, thus decreasing GR levels. Another limitation of this study is that the frequencies and phenotype of Th17.1 were not analyzed before natalizumab treatment, which possibly differs between responders and nonresponders. GR can also be alternatively controlled posttranscriptionally, but remains a challenge to detect at the protein level, let alone in distinct Th subsets.

---

**Figure 4** Presence of MDR1+Th17.1 cells in postmortem white matter tissue of patients with MS

Representative immunohistochemical staining for CD4 and MDR1 (A) as well as human leukocyte antigen II (HLA-II), myelin oligodendrocyte glycoprotein (MOG), microtubule-associated protein 2 (MAP2) (B) in formalin-fixed, paraffin-embedded white matter lesions of 3 MS donors. Images were taken with a ×20 digital magnification, and lesions were classified as active and postdemyelinating (MS-1), active and demyelinating (MS-2), and mixed active/inactive and demyelinating (MS-3). (C) Coexpression of CD4 (red) and MDR1 (green) in 4',6-diamidino-2-phenylindole (blue)-positive cells in these brain tissues, as determined by immunofluorescence staining. (D) Representative gating of ex vivo CCR6+ Th subsets and MDR1+ fractions of Th17.1 (CCR6+CXCR3+CCR4−/dim) in the blood, meninges, and brain tissue from the same MS donor. (E) Frequencies of MDR1+ Th17, Th17 DP, and Th17.1 cells in freshly isolated single-cell suspensions from postmortem blood, meninges, and brain tissues from 8 late-stage MS donors, as determined by FACS. A total of 14 brain tissues from 8 donors were analyzed. Data were compared using a nonrepeated measurement 2-way ANOVA with a post hoc Bonferroni multiple comparison test. *p < 0.05 and ****p < 0.0001. MDR1 = multidrug resistance protein 1; Th = T helper.
Apart from the role of MDR1 and GR in GC resistance, both molecules also play a critical role in the induction of neuroinflammation. Increased GR signaling in pathogenic T cells protects from CNS autoimmunity, whereas deletion of GR abrogates this phenomenon in EAE. Deletion of ABCB1 resulted in a similar protective phenotype. These studies at least suggest that the low GR and high MDR1 expression in brain-homing Th17.1 drives neuroinflammation. Quantification of in situ localization of MDR1+ Th cells also for patients with other neurologic diseases should be performed to better interpret their role in MS brain pathology. Because of their involvement in GC resistance and local inflammation, MDR1 and GR are promising targets to improve GC efficacy in early MS. The need for improving this efficacy is underlined by the increased MDR1-mediated efflux ratio of methylprednisolone, the standard treatment of acute MS relapses.

A recent study showed that low vitamin D levels are associated with GC-resistant relapses in patients with MS. Although controversial results were obtained from clinical trials with respect to disease activity, increasing vitamin D levels improved GC efficacy and suppressed EAE induction in mice via Th-cell intrinsic upregulation of NR3C1. Because vitamin D also downregulates CCR6 on Th cells, this steroid hormone may be exploited to enhance GC efficacy in MS by sensitizing Th17.1 cells. MDR1 activity can also be blocked by other types of steroids and even by anti-CD20 antibodies. The selective targeting of MDR1 is further supported by its additional role in proinflammatory cytokine excretion and trafficking of T cells across the blood-brain barrier. However, the implementation of such strategies should also be taken with care because MDR1 is expressed by many other cell types. In-depth analysis of Th17.1 cells by currently available single-cell platforms would reveal additional targets that can be used for the design of small-molecule therapeutics. The predominance of Th17.1 in the CSF of patients with early MS could set the stage for its use as a marker to predict disease activity.

**Acknowledgment**

This study was performed within the Erasmus Postgraduate School Molecular Medicine. The authors are thankful to their FACS operators Harm de Wit and Peter van Geel for sorting. They thank all patients and healthy individuals for donating biological material. They dedicate this article to Professor Rogier Q. Hintzen, who died on May 15, 2019. They will continue his research in their MS Center with the same drive and passion as he did.

**Study funding**

Dutch MS Research Foundation (15-490d MS and 16-952 MS).

**Disclosure**

S.C. Koetzier, J. van Langelaar, K.M. Blok, T.P.P. van den Bosch, A.F. Wierenga-Wolf, M.-J. Melief, K. Pol, T.A. Siepman, and G.M.G.M. Verjans report no disclosures relevant to the manuscript. J. Smolders received lecture and/or consultancy fee from Biogen, Merck, Novartis, and Sanofi-Genzyme. E. Lubberts, H.E. de Vries, and M.M. van Luijn report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

**Publication history**

Received by Neurology: Neuroimmunology & Neuroinflammation May 7, 2020. Accepted in final form August 20, 2020.

## Appendix Authors

| Name                         | Location                              | Contribution                                      |
|------------------------------|---------------------------------------|--------------------------------------------------|
| Steven C. Koetzier            | Erasmus MC and MS Center              | Designed, performed, and analyzed the data; contributed to the study concept; and wrote the paper |
| Jamie van Langelaar           | Erasmus MC and MS Center              | Designed, performed, and analyzed the data and contributed to the study concept |
| Katelijn M. Blok, MD          | Erasmus MC and MS Center              | Collected clinical samples, patient information, and contributed to the study concept |
| Thierry P.P. van den Bosch, PhD | Erasmus MC, University Medical Center, Rotterdam, the Netherlands | Performed experiments and analyzed data |
| Annet F. Wierenga-Wolf        | Erasmus MC and MS Center              | Performed experiments and analyzed data |
| Marie-José Melief            | Erasmus MC and MS Center              | Performed experiments and analyzed data |
| Kim Pol                      | Erasmus MC and MS Center              | Performed experiments and analyzed data |
| Georges M.G.M. Verjans, PhD   | Erasmus MC and MS Center              | Shared his protocol for isolating single cells from brain tissues |
| Joost Smolders MD, PhD        | Erasmus MC and MS Center              | Contributed to the study concept |
| Erik Lubberts, PhD            | Erasmus MC, University Medical Center, Rotterdam, the Netherlands | Contributed to the study concept |
| Helga E. de Vries, PhD        | Amsterdam University Medical Center and MS Center Amsterdam, Amsterdam, the Netherlands | Selected and provided postmortem brain tissues and contributed to the study concept |
| Marvin M. van Luijn, PhD      | Erasmus MC and MS Center              | Designed the experiment, wrote the paper, supervised the project, and acquired funding |
References

1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545–558.

2. Kriger S, Sorrells SF, Nickerson M, Pace TW. Mechanistic insights into corticosteroids in multiple sclerosis: war horse or chameleon? Clin Neurol Neurosurg 2019;176:11–16.

3. Bruasferri F, Candela L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435–442.

4. van Winsen LM, Muris DF, Polman CH, Dijkstra CD, van den Berg TK, Uitdehaag BM. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 2005;90:734–740.

5. Ysrraelit MC, Gaitán MI, Lopez AS, Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008;71:1948–1954.

6. Bossmann M, Di Rienzo A, Caux C, Menetrier-Caux C. MDR1 in immunity: friend or foe? Oncoimmunology 2018;7:e1499388.

7. Schweinruber N, Fischer HJ, Fischer L, et al. Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses. Acta Neuropathol 2014;127:713–729.

8. Wiust S, van den Brandt J, Tischner D, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008;180:8434–8443.

9. Ciccone A, Beretta S, Bruasferri F, Galea I, Protti A, Spreafo C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008:CD006264.

10. Reboldi A, Coisne C, Baumjohann D, et al. p110delta and P-glycoprotein: additive effects on the brain endothelial cell line. FASEB J 2005;19:1872–1874.

11. Liston A, Kohler RE, Townley S, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis in mice. Neuropathol 2017;134:383.

12. Maeda S, Osaga S, Maeda T, et al. Circulating Th17.1 cells as candidate for the presentation of myelin antigens by the brain endothelium guides antigen-specific B cell responses. Acta Neuropathol 2001;15:1062–1077.

13. Biola A, Afarka A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertolasi L, Pallardy M, Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAS (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001;15:1062–1076.

14. Paulissen SM, van Hamburg JP, Dankers W, Lubberts E. ABCB1 transporter discriminates human resting naive T cells from cycling transitional and memory B cells. Eur J Immunol 2005;35:39–401.

15. Biola A, Afarka A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertolasi L, Pallardy M, Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAS (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001;15:1062–1076.

16. Nvanderyver S, Deadiator L, Libert C. Comprehensive overview of the structure and function of the glucocorticoid receptor. Endocr Rev 2014;35:671–693.

17. Nvanderyver S, Deadiator L, Libert C. Comprehensive overview of the structure and function of the glucocorticoid receptor. Endocr Rev 2014;35:671–693.

18. van Nierop GP, van Luijn MM, Michels SS, et al. Phenotypic and functional characteristics of P-glycoprotein+ Th17 cell populations in rheumatoid arthritis. Cytokine 2015;74:43–53.

19. Dankers W, Gonzalez-Leal C, Davelaar N, et al. 1,25(OH)2D3 and dexamethasone additively suppress synovial fibroblast activation by CCR6+ T helper memory cells and enhance the effect of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

20. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006;63:1383–1387.

21. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

22. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

23. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

24. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

25. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

26. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

27. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

28. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

29. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

30. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.

31. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of tumor necrosis factor alpha blockade. Arthritis Res Ther 2018;20:212.
Brain-homing CD4+ T cells display glucocorticoid-resistant features in MS
Steven C. Koetzier, Jamie van Langelaar, Katelijn M. Blok, et al.

Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000894

This information is current as of October 9, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/7/6/e894.full.html

References
This article cites 47 articles, 9 of which you can access for free at:
http://nn.neurology.org/content/7/6/e894.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus